Eliquis (apixaban) is a prescription anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is one of the most widely prescribed anticoagulants, and is considered to be an effective and safe treatment option for many patients. However, there are potential risks associated with Eliquis, particularly in the elderly population. This article will discuss the potential risks of Eliquis in the elderly, including side effects, potential interactions with other medications, and the importance of monitoring for adverse reactions.
Eliquis is a direct factor Xa inhibitor, which works by blocking the action of factor Xa, a protein involved in the clotting process. This helps to prevent the formation of blood clots, which can cause serious health problems such as stroke, heart attack, and pulmonary embolism. Eliquis is generally well-tolerated, but it is important to be aware of the potential risks associated with taking this medication.
The elderly population is particularly vulnerable to the side effects of Eliquis. Common side effects of Eliquis include nausea, headache, dizziness, and fatigue. Elderly patients may also be more likely to experience bleeding, including bleeding from the nose, gums, or rectum, as well as bruising more easily. In some cases, Eliquis can also cause anemia, which can lead to fatigue and shortness of breath.
Eliquis can interact with other medications, including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and other anticoagulants. It is important to discuss all medications that a patient is taking with their doctor, as some medications may increase the risk of bleeding or other side effects when taken with Eliquis.
It is important for elderly patients taking Eliquis to be monitored closely for any adverse reactions, such as bleeding or bruising. Patients should also be aware of the signs and symptoms of anemia, such as fatigue and shortness of breath. Regular blood tests should be done to monitor for any changes in the blood.
Eliquis is a widely prescribed anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. While Eliquis is generally well-tolerated, there are potential risks associated with taking this medication, particularly in the elderly population. It is important to be aware of the potential side effects of Eliquis, as well as any potential interactions with other medications. Regular monitoring for adverse reactions is also important, as this can help to detect any problems early and reduce the risk of serious complications.
1.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
2.
How artificial intelligence could significantly improve the prognosis for cancer patients.
3.
Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.
4.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
5.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
1.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
2.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
3.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
4.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
5.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation